2-[[4-氨基-5-[5-碘-4-甲氧基-2-(1-甲基乙基)苯氧基]-2,4-嘧啶基]氨基]-1,3-丙二醇 | 1050670-85-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-[[4-氨基-5-[5-碘-4-甲氧基-2-(1-甲基乙基)苯氧基]-2,4-嘧啶基]氨基]-1,3-丙二醇
• 中文别名: 2-[[4-氨基-5-[5-碘-4-甲氧基-2-(异丙基)苯氧基]-2-嘧啶基]氨基]-1,3-丙二醇
• 英文名称: RO-51
• 英文别名: 2-[4-amino-5-(5-iodo-2-isopropyl-4-methoxy-phenoxy)-pyrimidin-2-ylamino]-propane-1,3-diol；2-((4-Amino-5-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidin-2-yl)amino)propane-1,3-diol；2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol
• CAS: 1050670-85-3
• 化学式: C₁₇H₂₃IN₄O₄
• 分子量: 474.299
• InChiKey: PAYROHWFGZADBR-UHFFFAOYSA-N

物化性质

• 溶解度：
  在 DMSO 中溶解度为 100 mM，在乙醇中溶解度为 100 mM

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  123
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N2-[2-(tert-butyl-dimethyl-silanyloxy)-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethyl]-5-(5-iodo-2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以84%的产率得到2-[[4-氨基-5-[5-碘-4-甲氧基-2-(1-甲基乙基)苯氧基]-2,4-嘧啶基]氨基]-1,3-丙二醇
  参考文献：
  名称：

  Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain

  摘要：

  The purinoceptor subtypes P2X(3) and P2X(2/3) have been shown to play a pivotal role in models of various pain conditions. Identification of a potent and selective dual P2X(3)/P2X(2/3) diaminopyrimidine antagonist RO-4 prompted subsequent optimization of the template. This paper describes the SAR and optimization of the diaminopyrimidine ring and particularly the substitution of the 2-amino group. The discovery of the highly potent and drug-like dual P2X(3)/P2X(2/3) antagonist RO-51 is presented. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.097

文献信息

• Diaminopyrimidines as P2X3 and P2X2/3 modulators
  申请人：Dillon Michael Patrick

  公开号：US20080207655A1

  公开（公告）日：2008-08-28

  Compounds of formula (I): wherein R 1 and R 2 are as defined herein. Also disclosed are methods of making and using the subject compounds.

  具有化学式（I）的化合物：其中R1和R2如本文所定义。还披露了制备和使用这些化合物的方法。
• EP3757103A1
  申请人：——

  公开号：EP3757103A1

  公开（公告）日：2020-12-30
• ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE
  申请人：Bayer Aktiengesellschaft

  公开号：EP3990453A1

  公开（公告）日：2022-05-04
• [EN] DIAMINOPYRIMIDINES<br/>[FR] DIAMINOPYRIMIDINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008104474A1

  公开（公告）日：2008-09-04

  [EN] Compounds of formula (I) wherein R¹ and R² are as defined herein. Also disclosed are methods of making and using the subject compounds.
  [FR] L'invention concerne des composés représentés par la formule (I) dans laquelle R¹ and R² sont tels que définis dans la description. L'invention concerne aussi des procédés de fabrication et d'utilisation de ces composés.
• [EN] ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE<br/>[FR] ANALOGUES DE3-(5-MÉTHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-MÉTHYL)PYRIMIDIN-5-YL]ÉTHYL}BENZAMIDE
  申请人：BAYER AG

  公开号：WO2020260463A1

  公开（公告）日：2020-12-30

  The present invention covers P2X3 inhibitor compounds of general formula (I) in which R1 and R2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic disorders, as a sole agent or in combination with other active ingredients.